Congenital Hyperinsulinism (CHI) Market

Jan 07, 2021

10 likes | 24 Views

Congenital Hyperinsulinism (CHI) is a condition that causes individuals to have abnormally high levels of insulin, which helps control blood sugar levels. In 2017, the total prevalent population of Congenital Hyperinsulinism (CHI) in 7MM was 21,852. It is observed that in the 7MM, both males and females are equally affected by Congenital Hyperinsulinism (CHI). As per Delveinsight, Congenital Hyperinsulinism (CHI) u2018s therapeutic market in the 7MM was USD 55.76 Million in 2017. Robust pipeline activity, increasing awareness of the disease, and availability of effective therapies are the key driver for the Congenital Hyperinsulinism (CHI) Market. The key companies in the Congenital Hyperinsulinism (CHI) market include Zealand Pharma, Rezolute, Xeris Pharmaceuticals, Eiger BioPharmaceuticals, Recordati, and many others. For more details on the Congenital Hyperinsulinism (CHI) Market, visit: https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market Source: Congenital Hyperinsulinism (CHI) Market

DelveInsight

Download Presentation

Congenital Hyperinsulinism (CHI) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D